Industry Symposium: New paradigms in the treatment of HR+HER2- mBC: CDK4/6 inhibitors and beyond
Supported by Novartis
Friday, October 12, 2018
13:30 – 14:30
| Chairpersons | Richard de Boer, Australia Hall B Belinda Yeo, Australia |
| 13:30 – 13:35 | Welcome Richard de Boer, Australia Belinda Yeo, Australia |
| 13:35 – 13:55 | Role of CDK4/6 Inhibitors in overcoming endocrine resistance: Are they all the same? Stephen Johnston, UK |
| 13:55 – 14:10 | CDK4/6 Inhibitors: The Australian experience, and what to do after progression? Elgene Lim, Australia |
| 14:10 – 14:30 | Case studies and panel discussion |